AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potential sales-based milestone payments, and a strong commercial partner experienced with commercialization in hospital settings Divestment allows AcelRx to prioritize resources on its late stage development assets, led by Niyad™, the lead nafamostat program with breakthrough device designation status from FDA Near-term corporate milestones expected by the end of Q2 2023 include the Niyad Emergency Use Authorization submission and the filing of a new drug application for the first of our two pre-filled syringe product candidates HAYWARD, Calif. , March 14, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora).

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

Study is the first to report on the use of DSUVIA® in the rapidly growing field of rhinology where otolaryngologists are performing painful nasal and sinus procedures in the office which were historically conducted only in ambulatory surgery centers or hospitals HAYWARD, Calif. , March 1, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a report arising from a series of rhinology procedures successfully performed using sufentanil sublingual tablet 30 mcg (SST; DSUVIA) in Otolaryngology Case Reports.

AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures

HAYWARD, Calif. , Dec. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 748,744 shares of its common stock, pre-funded warrants exercisable for an aggregate of 2,632,898 shares of common stock and common warrants exercisable for an aggregate of 4,227,052 shares of common stock.

AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

Soleno Therapeutics

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.

Three Healthcare Penny Stocks to Watch In The New Year

Patients reported lower pain scores, required fewer rescue doses and had a shorter hospital stay than patients receiving continuous femoral nerve block This study of patients following knee replacement surgery adds to a growing database supporting the benefits of using sufentanil sublingual tablets for surgical pain management HAYWARD, Calif. , Dec. 8, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a recent retrospective study published in the Journal of Clinical Medicine Special Issue "Advances in Postoperative Pain Management and Postoperative Chronic Pain".

AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Thomas Lee - HC Wainwright & Company Operator Welcome to the AcelRx Third Quarter 2022 Earnings Call. This call is being webcast live via the Events page of the Investors section of AcelRx's website at www.acelrx.com.

AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call Transcript

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $20.9 million in cash and short-term investments as of September 30, 2022 Webcast and Conference Call to be held today at 4:30 p.m. EDT HAYWARD, Calif.

AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

HAYWARD, Calif. , Nov. 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),  a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Monday, November 14, 2022.

AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

The study of 324 complex plastic surgery procedures demonstrated many benefits of using DSUVIA for analgesia, including avoiding the need for general anesthesia HAYWARD, Calif. , Oct. 31, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" was presented on Friday, October 28 th by Jeffrey DeWeese, M.D.

AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

Physicians across Europe will now have access to DZUVEO®, a novel sublingual approach to acute pain management in medically supervised settings HAYWARD, Calif. , Oct. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that its commercial partner, Laboratorie Aguettant ("Aguettant"), has launched DZUVEO® (sufentanil sublingual tablet, 30 mcg), which is branded as DSUVIA® in the U.S., across Europe.

AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant

Brigham and Women's Hospital study found that SST-treated patients had significantly lower pain scores in the post-operative care unit (PACU) compared with patients in the two intravenous opioid control groups following major spine surgery HAYWARD, Calif. , Oct. 26, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the results of a 190-patient, investigator-initiated trial conducted at Brigham and Women's Hospital in Boston, MA, entitled, "The Impact of Sublingual Sufentanil on Postoperative Pain Control in Patients Undergoing Spine Surgery" (abstract # A4262), was presented at the ANESTHESIOLOGY® 2022 annual meeting, held October 21-25, 2022 in New Orleans, LA.

AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022

HAYWARD, Calif. , Oct. 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of 1-for-20.

AcelRx Pharmaceuticals Announces Reverse Stock Split

Presentation concludes that future battlefield medicine efforts should focus on newer analgesics like DSUVIA® across military settings and establish protocols for their implementation in the trauma setting HAYWARD, Calif. , Oct. 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract entitled, "Evolution Of Opioid Analgesia On The Battlefield For Moderate-to-Severe Acute Pain" (abstract # A4123) was presented by lead author, Sharon Kim, M.S.

AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences

Experts from the Uniformed Services University of the Health Sciences conclude that future battlefield medicine efforts should focus on newer analgesics like DSUVIA® across military settings and establish protocols for their implementation HAYWARD, Calif. , Aug. 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract entitled, "Evolution Of Opioid Analgesia On The Battlefield For Moderate-to-Severe Acute Pain" (abstract # A4123) was accepted for e-Abstract presentation at the ANESTHESIOLOGY® 2022 annual meeting, being held October 21-25, 2022 in New Orleans, LA.

AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

AcelRx's 2Q22 Earnings Release and Call provided little tangible news. However, it becomes more and more obvious that ACRX's management is fully shifting the focus from commercial DSUVIA to launching the Syringes products and Niyad.

AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Pamela Palmer - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Ed Arce - HC Wainwright & Company Operator Welcome to the AcelRx Second Quarter, 2022 Earnings Call. This call is being webcast live on the Events page of the Investors section of AcelRx's website at www.acelrx.com.

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2022 Results - Earnings Call Transcript

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

Advanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023 $0.6 million net revenue in Q2 2022; fifth consecutive quarter of commercial (ex-DoD) sales volume growth for DSUVIA, with a 133% increase compared to Q2 2021; on track for EU launch of DZUVEO in the third quarter Projected annual savings of $9 million beginning in June 2022 from realigned cost structure $27.9 million in cash and short-term investments as of June 30, 2022 $84.1 million gain on extinguishment of debt due to termination of royalty monetization Webcast and Conference Call to be held today at 4:30 p.m. EDT HAYWARD, Calif.

AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Source: Shutterstock AcelRx Pharmaceuticals (NASDAQ: ACRX ) stock is seeing major gains on Thursday after announcing a presentation for the upcoming Plastic Surgery: The Meeting 2022. That meeting is set to take place from Oct. 27 to Oct. 30 in Boston, Mass.

Why Is AcelRx (ACRX) Stock up 26% Today?

HAYWARD, Calif. , Aug. 11, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" has been accepted for podium presentation at Plastic Surgery: The Meeting 2022, taking place October 27-30, 2022 in Boston, MA.

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022

The stock price of AcelRx Pharmaceuticals (ACRX) skyrocketed over 70% pre-market today. This is why.

AcelRx Pharmaceuticals (ACRX) Stock: Why It Skyrocketed Over 70% Today

HAYWARD, Calif. , Aug. 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, "The Impact of Sublingual Sufentanil on Postoperative Pain Control in Patients Undergoing Spine Surgery" (abstract # A4262) was accepted for e-Abstract presentation at the ANESTHESIOLOGY® 2022 annual meeting, being held October 21-25, 2022 in New Orleans, LA.

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

HAYWARD, Calif. , July 28, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022.

AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022

Ebang International Holdings

Titan Pharma

Here's what you need to know about trading penny stocks on July 8th The post What to Know About Buying Penny Stocks on July 8th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for AcelRx Pharmaceuticals Stock (ACRX)